The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Prognostic factors for survival in melanoma patients with brain metastases
Abstract
BACKGROUND: One of the most common and deadly complications of melanoma is brain metastases. The outcomes of advanced melanoma patients who developed brain metastases were reviewed to identify significant prognostic factors for overall survival (OS). METHODS: An institutional database of advanced melanoma patients enrolled on clinical trials in the Department of Melanoma Medical Oncology from 1986 to 2004 was reviewed and patients who developed brain metastases were identified. Date of diagnosis, patient age, pattern of brain involvement, timing relative to extracranial metastases, prior response to systemic therapy, and treatments given for brain metastases were assessed as potential prognostic factors for OS. RESULTS: Among 743 melanoma patients enrolled in clinical trials for regional or systemic metastatic disease, 330 (44%) patients developed brain metastases. The median OS after the diagnosis of brain metastases was 4.7 months. Diagnosis before 1996, increased number of parenchymal brain metastases, leptomeningeal involvement, and development of brain metastases after receiving systemic therapy for extracranial metastases were found to be significant prognostic factors for OS. Among patients who received systemic therapy as the initial treatment of brain metastases, patients who previously responded to systemic therapies had longer survival than patients who had not responded. CONCLUSIONS: The era, pattern, and timing of melanoma brain metastases were found to be strongly associated with survival. Previous responsiveness to systemic therapies did not predict better outcomes overall, but it did correlate with improved survival for patients with brain metastases who were treated with systemic therapies. These factors may be used in guiding patient management and for stratifying patients in clinical trials. Cancer 2011. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,135
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationGaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationImmunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Kocher, M., Soffietti, R., Abacioglu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., Bhatt, A., Jensen, A. W., Brown, P. D., Shih, H., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.025 · Cited by 985
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Self-citationLong, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Self-citationNRAS mutation status is an independent prognostic factor in metastatic melanoma
Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2012) · Cancer · doi:10.1002/cncr.26724 · Cited by 689
Self-citationDemographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
Sampson, J. H., Carter, J. H., Friedman, A. H., & Seigler, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0011 · Cited by 560
Xie, T.-X., Wei, D., Liu, M., Gao, A. C., Ali-Osman, F., Sawaya, R., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207383 · Cited by 550
Determinants of Outcome in Melanoma Patients With Cerebral Metastases
Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.140 · Cited by 445
Menzies, A. M., Haydu, L. E., Visintin, L., Carlino, M. S., Howle, J. R., Thompson, J. F., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0052 · Cited by 434
Radvanyi, L. G., Bernatchez, C., Zhang, M., Fox, P. S., Miller, P., Chacon, J., Wu, R., Lizee, G., Mahoney, S., Alvarado, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1177 · Cited by 427
Self-citationActivation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
Eton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.044 · Cited by 370
Self-citationMultidisciplinary Management of Brain Metastases
Eichler, A. F., & Loeffler, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-884 · Cited by 366
Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., Buzaid, A., Skarlos, D., & Rankin, E. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.044 · Cited by 360
Knisely, J. P. S., Yu, J. B., Flanigan, J., Sznol, M., Kluger, H. M., & Chiang, V. L. S. (2012) · Journal of Neurosurgery · doi:10.3171/2012.5.jns111929 · Cited by 330
Atkins, M. B., Hsu, J., Lee, S., Cohen, G. I., Flaherty, L. E., Sosman, J. A., Sondak, V. K., & Kirkwood, J. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5448 · Cited by 320
Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3477 · Cited by 302
Di Giacomo, A. M., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., Marasco, A., Rivoltini, L., Simeone, E., Nicoletti, S. V., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70324-8 · Cited by 284
Raizer, J. J., Hwu, W.-J., Panageas, K. S., Wilton, A., Baldwin, D. E., Bailey, E., von Althann, C., Lamb, L. A., Alvarado, G., Bilsky, M. H., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-058 · Cited by 230
Self-citationReduced local recurrence of a single brain metastasis through microscopic total resection
Yoo, H., Kim, Y. Z., Nam, B. H., et al. (2008) · Journal of neurosurgery · doi:10.3171/2008.8.jns08448 · Cited by 202
Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
Hong, J. J., Rosenberg, S. A., Dudley, M. E., Yang, J. C., White, D. E., Butman, J. A., & Sherry, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1507 · Cited by 191
Leptomeningeal metastases from solid malignancy: a review
Taillibert, S., Laigle-Donadey, F., Chodkiewicz, C., Sanson, M., Hoang-Xuan, K., & Delattre, J.-Y. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8101-x · Cited by 169
Analysis of the genome to personalize therapy for melanoma
Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 165
Self-citationCranial irradiation after surgical excision of brain metastases in melanoma patients
Skibber, J. M., Soong, S.-J., Austin, L., Balch, C. M., & Sawaya, R. A. (1996) · Annals of Surgical Oncology · doi:10.1007/bf02305789 · Cited by 149
Margolin, K. A., Atkins, M. B., Thompson, J. F., Ernstoff, M. S., Weber, J. S., Flaherty, L. E., Clark, J. I., Weiss, G. R., Sosman, J. A., Smith, J. W., et al. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0323-8 · Cited by 145
Niessner, H., Forschner, A., Klumpp, B. D., Honegger, J. B., Witte, M. B., Bornemann, A., Dummer, R., ADAM, A., Bauer, J. M., Tabatabai, G., et al. (2012) · Cancer Medicine · doi:10.1002/cam4.50 · Cited by 143
Grandhi, R., Kondziolka, D. S., Panczykowski, D. M., Monaco, E. A., Kano, H., Niranjan, A., Flíckinger, J. C., & Lunsford, L. D. (2012) · Journal of neurosurgery · doi:10.3171/2012.4.jns11870 · Cited by 127
Amaravadi, R. K., Schuchter, L. M., McDermott, D. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2074 · Cited by 117
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
Weber, J. S., Amin, A., Minor, D. R., Siegel, J., Berman, D., & O'Day, S. J. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834d3d88 · Cited by 113
Temozolomide: a novel oral alkylating agent
Danson, S. J., & Middleton, M. R. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.1.13 · Cited by 113
Temozolomide plus thalidomide in patients with brain metastases from melanoma: A Phase II study
Hwu, W., Lis, E., Menell, J. H., Panageas, K. S., Lamb, L. A., Merrell, J., Williams, L. J., Krown, S. E., Chapman, P. B., Livingston, P. O., et al. (2005) · Cancer · doi:10.1002/cncr.21081 · Cited by 102
Self-citationAtkins, M. B., Sosman, J. A., Agarwala, S. S., Logan, T. F., Clark, J. I., Ernstoff, M. S., Lawson, D., Dutcher, J. P., Weiss, G. R., Curti, B. D., et al. (2008) · Cancer · doi:10.1002/cncr.23805 · Cited by 80
Postoperative radiation for lung cancer metastatic to the brain.
Armstrong, J. G., Wroński, M., Galicich, J. H., Arbit, E., Leibel, S., & BURT, M. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2340 · Cited by 74
Krown, S. E., Niedzwiecki, D., Hwu, W., Hodgson, L. C., Houghton, A. N., Haluska, F. G., & for the Cancer and Leukemia Group B (2006) · Cancer · doi:10.1002/cncr.22239 · Cited by 62
Self-citationEisen, T. G., Marais, R., Affolter, A., Lorigan, P. C., Robert, C., Corrie, P. G., Ottensmeier, C. H. H., Chevreau, C., Chao, D., Nathan, P., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.257 · Cited by 46
Larkin, J., Hughes, S., Beirne, D., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603503 · Cited by 44
Kim, K. B., Legha, S. S., Gonzalez, R. C., Anderson, C. M., Johnson, M. M., Liu, P., Papadopoulos, N. E., Eton, O. E., Plager, C., Buzaid, A. C., et al. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e328314b84a · Cited by 39
Self-citationThe Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival
Lee, I. Y., Fox, P. S., Ferguson, S. D., Bassett, R., Kong, L., Schacherer, C. W., Gershenwald, J. E., Grimm, E. A., Fuller, G. N., & Heimberger, A. B. (2012) · Oncotarget · doi:10.18632/oncotarget.475 · Cited by 31
Bedikian, A. Y., Johnson, M. M., Warneke, C. L., McIntyre, S. E., Papadopoulos, N., Hwu, W., Kim, K., & Hwu, P. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910802131519 · Cited by 31
Self-citationCentral Nervous System Metastases of Cutaneous Malignant Melanoma: A Population-based Study
Cohn-Cedermark, G. E., Månsson‐Brahme, E., Rutqvist, L. E., Larsson, O., Johansson, H., & Ringborg, U. K. (1998) · Acta Oncologica · doi:10.1080/028418698430412 · Cited by 26
Complete Response of Multiple Melanoma Brain Metastases after Treatment with Temozolomide
Dvořák, J., Melichar, B., Žižka, J., Hadzi-Nikolov, D., & Petera, J. (2004) · Oncology Research and Treatment · doi:10.1159/000076908 · Cited by 12
Cited by
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,321
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 987
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Self-citationLong, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Self-citation
Metadata
- Authors
- Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W., Hwu, P., & Bedikian, A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-10-19
- Volume
- 117
- Issue
- 8
- Pages
- 1687-1696
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1968221752
- Cited by
- 548
- References
- 59
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.